Real world cohort study of Japanese chronic hepatitis C patients to assess the effectiveness of Japan- approved direct-acting antiviral (DAA)
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 21 Dec 2018 New trial record
- 24 Oct 2018 Results presented at the 26th United European Gastroenterology Week